Physician profile
Eric B Baud
NPI 1265431654
$7,744.21
in general payments reported to CMS, 2019-2025
28 companies · $885 in 2025
The $885 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,651 · 2020: $930 · 2021: $1,016 · 2022: $1,129 · 2023: $1,279 · 2024: $854 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.91 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,897.06 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Galderma Laboratories, L.P. | $1,079.91 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Novartis Pharmaceuticals Corporation | $771.24 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $642.05 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Janssen Biotech, INC. | $607.63 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $476.99 | 2019-2024 | Taltz, Olumiant |
| Pfizer INC. | $391.56 | 2019-2025 | |
| Leo Pharma INC. | $384.42 | 2020-2023 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $335.55 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $227.86 | 2019-2025 | Libtayo, Dupixent |
| Ucb, INC. | $197.92 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $163.82 | 2019-2023 | |
| Dermavant Sciences, INC. | $150.57 | 2023-2024 | Vtama |
| Mylan Institutional INC. | $46.02 | 2023 | Hulio |
| Organon LLC | $44.99 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocon Biologics INC | $43.58 | 2024 | Hulio |
| Genentech USA, INC. | $43.02 | 2019 | |
| Almirall LLC | $38.16 | 2022-2023 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.36 | 2022-2024 | Cyltezo |
| Mission Pharmacal Company | $25.54 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $21.83 | 2019 | |
| Incyte Corporation | $20.35 | 2022 | |
| Arcutis Biotherapeutics, INC. | $18.98 | 2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.00 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $17.80 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.57 | 2023 | Ycanth |
| Allergan, INC. | $15.79 | 2019 | |
| Mayne Pharma Commercial LLC | $9.64 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Baud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.